Supriya Lifescience
687.60
-2.30(-0.33%)
Market Cap₹5,534.00 Cr
PE Ratio29.99
IndustryHealthcare
Company Performance:
1D-0.33%
1M-6.70%
6M+4.02%
1Y+9.55%
5Y+75.92%
View Company Insightsright
More news about Supriya Lifescience
01Sept 25
Supriya Lifescience Sets Ambitious Growth Targets, Eyes US Market Expansion
Supriya Lifescience has announced a comprehensive growth strategy aiming for 33-35% EBITDA margins by FY26 and Rs 1,000 crore revenue by FY27. The plan includes launching 3-4 new products annually, entering the US market, and investing Rs 200 crore over three years for a new site in Patalganga. The company has already launched a new anaesthetic product and is in talks for a potential blockbuster with a $7 billion market. Supriya is focusing on regulated markets with USFDA-compliant facilities and emphasizing backwards integration to compete effectively against Chinese manufacturers.
 no imag found
01Jul 25
Supriya Lifescience Faces ₹603.8 Crore Tax Demand
Supriya Lifescience, a pharmaceutical company, has received a tax demand notice of ₹603.80 crore from the Tax Department. The company has not provided specific details about the nature of the tax assessment or the period it covers. This substantial demand could potentially impact the company's finances and operations. Investors are awaiting further information and the company's response to this development.
 no imag found
29May 25
Supriya Lifescience Unveils Ambitious Growth Strategy, Targets ₹1,000 Crore Revenue by FY27
Supriya Lifescience announced robust growth plans during a recent conference call. The company's formulation facility is expected to generate ₹450-500 crore in revenue. They maintained a 20% annual revenue growth guidance with EBITDA margins of 33-35%. A mid-term goal of ₹1,000 crore revenue by FY2027 was set. The company anticipates stronger volume growth over the next two years, driven by full capacity utilization of Module E by FY27 and launch of new products with significant global volume potential.
 no imag found
27May 25
Supriya Lifescience Reports Strong Q4 Results, Announces Dividend
Supriya Lifescience Ltd. has released its Q4 financial results, showing significant year-over-year growth. Revenue increased by 16.46% to ₹1,840.00 million, EBITDA rose by 21.80% to ₹676.00 million, and net profit surged by 36.59% to ₹504.00 million. The company's EBITDA margin expanded to 36.72% from 35.09% in the previous year. Quarter-on-quarter growth was also notable, with net profit increasing by 7.69%. The board has recommended a dividend of ₹1.00 per equity share.
 no imag found
Supriya Lifescience
687.60
-2.30
(-0.33%)
1 Year Returns:+9.55%
Industry Peers
Sun Pharmaceutical
1,719.00
(-0.31%)
Divis Laboratories
6,323.00
(+0.63%)
Torrent Pharmaceuticals
4,235.40
(+0.58%)
Cipla
1,337.80
(-0.89%)
Dr Reddys Laboratories
1,287.30
(+0.55%)
Lupin
2,238.40
(+0.53%)
Zydus Life Science
906.55
(-0.38%)
Mankind Pharma
2,050.90
(-1.19%)
Aurobindo Pharma
1,184.20
(+2.12%)
Alkem Laboratories
5,406.00
(-1.06%)